Iqvia (NYSE:IQV) had its price target dropped by equities researchers at Barclays from $192.00 to $166.00 in a research report issued on Thursday, BenzingaRatingsTable reports. The firm presently has an “overweight” rating on the medical research company’s stock. Barclays‘s price objective suggests a potential upside of 50.17% from the company’s current price.
Several other brokerages also recently issued reports on IQV. Deutsche Bank began coverage on shares of Iqvia in a research note on Monday, March 2nd. They issued a “buy” rating and a $190.00 price objective on the stock. ValuEngine upgraded shares of Iqvia from a “sell” rating to a “hold” rating in a research note on Saturday, February 15th. Robert W. Baird raised their price objective on shares of Iqvia from $172.00 to $181.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. UBS Group raised their price objective on shares of Iqvia from $187.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Finally, Stifel Nicolaus raised their price objective on shares of Iqvia from to and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $169.06.
IQV stock traded up $5.66 during midday trading on Thursday, hitting $110.54. 102,256 shares of the company traded hands, compared to its average volume of 2,813,541. Iqvia has a twelve month low of $81.79 and a twelve month high of $169.14. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 1.91. The business has a 50 day simple moving average of $138.81 and a 200-day simple moving average of $147.25. The stock has a market capitalization of $18.64 billion, a price-to-earnings ratio of 113.08, a price-to-earnings-growth ratio of 1.05 and a beta of 0.94.
Iqvia (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 12th. The medical research company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.72 by $0.02. Iqvia had a return on equity of 17.65% and a net margin of 1.72%. The company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter last year, the company posted $1.50 earnings per share. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. Equities research analysts forecast that Iqvia will post 6.62 EPS for the current year.
In other Iqvia news, CFO Michael R. Mcdonnell sold 12,000 shares of Iqvia stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the completion of the transaction, the chief financial officer now directly owns 14,366 shares of the company’s stock, valued at $2,227,735.62. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael J. Evanisko sold 6,250 shares of Iqvia stock in a transaction on Friday, January 17th. The shares were sold at an average price of $160.76, for a total value of $1,004,750.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 740,828 shares of company stock valued at $121,469,155. Company insiders own 6.00% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of IQV. RMR Wealth Builders bought a new position in shares of Iqvia in the fourth quarter valued at about $27,000. Penserra Capital Management LLC raised its holdings in shares of Iqvia by 57.5% in the fourth quarter. Penserra Capital Management LLC now owns 189 shares of the medical research company’s stock valued at $29,000 after buying an additional 69 shares during the last quarter. Orion Portfolio Solutions LLC bought a new position in shares of Iqvia in the fourth quarter valued at about $32,000. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Iqvia by 379.5% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 211 shares of the medical research company’s stock valued at $33,000 after buying an additional 167 shares during the last quarter. Finally, Evolution Wealth Advisors LLC raised its holdings in shares of Iqvia by 303.6% in the fourth quarter. Evolution Wealth Advisors LLC now owns 222 shares of the medical research company’s stock valued at $34,000 after buying an additional 167 shares during the last quarter. 89.25% of the stock is owned by institutional investors.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading: Why is momentum important to successful trading?
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.